Details

Autor(en) / Beteiligte

• GIEBEL, S
• KRUZEL, T
• GLOWALA-KOSINKA, M
• CHWIEDUK, A
• MITRUS, I
• SMAGUR, A
• HOLOWIECKI, J
• CZERW, T
• SADUS-WOJCIECHOWSKA, M
• NAJDA, J
• CHMIELOWSKA, E
• GROSICKI, S
• JURCZYSZYN, A
• PASIARSKI, M
• NOWARA, E

Titel

Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers

Ist Teil von

• Bone marrow transplantation (Basingstoke), 2013-07, Vol.48 (7), p.915-921

Ort / Verlag

Basingstoke: Nature Publishing Group

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• The optimal protocol for mobilization of hematopoietic stem cells in patients with lymphoid malignancies has not been determined so far. We retrospectively analyzed the efficacy and safety of Ara-C at a dose of 1.6 g/m(2) compared with CY at a dose of 4.0 g/m(2), both combined with filgrastim. Seventy and forty-five patients, respectively, were included, among whom 60% were defined as 'predicted poor mobilizers'. The use of Ara-C was associated with significantly higher peak number of circulating CD34(+) cells compared with CY (P<0.0001). In the Ara-C group, 95% of patients with multiple myeloma (MM) collected at least 5 × 10(6) CD34(+) cells/kg required for tandem transplantation, and 97% of lymphoma patients collected at least 2 × 10(6) CD34(+) cells/kg, needed for a single autologous hematopoietic SCT (autoHSCT), which was achieved with a single leukapheresis in 91% of cases. Results for the CY group were significantly inferior (P<0.0001). No patient mobilized with Ara-C experienced febrile neutropenia, whereas 35% required platelet transfusions. Among patients who proceeded to autoHSCT, the time of both neutrophil and platelet recovery was significantly shorter for those mobilized with Ara-C than CY. We conclude that intermediate-dose Ara-C+filgrastim is a very effective and relatively safe mobilization protocol for patients with lymphoid malignancies.